Survival for patients undergoing allogeneic hematopoietic cell transplantation (HCT) has significantly improved over time, according to a study of 38,060 patients with hematologic malignancies transplanted between 1994 and 2005 and reported to CIBMTR (Center for International Blood and Marrow Transplant Research). The authors note that despite a median age increase from 33 to 40 years during the 12-year period, one-year survival improved significantly in patients undergoing unrelated donor HCT: 48% to 63%; p=0.003. Survival in patients undergoing sibling HCT also improved, but the difference was not statistically significant. Survival at 100 days post-transplant was significantly improved for patients with acute myeloid leukemia in first complete remission after myeloablative sibling HCT (85% to 94%) and unrelated donor HCT (63% to 86%); p<0.001. Similar improvements were seen for acute lymphoblastic leukemia and myelodysplastic syndromes.